GFAP and Cognitive impairment: Glial fibrillary acidic protein (GFAP) as a marker of glial activation was first reported to increase and to correlate with cognitive impairment in AD patients in 2019 [96] and has since been validated as a valuable biomarker for AD, although with significant variability.